Болезнь Паркинсона: новые методы стимуляции глубоких структур мозга и роль микробиоты кишечника в патогенезе заболевания (литературный обзор)

1. Веругина Н.И., Левин О.С., Ляшенко Е.А. Роль кишечной микробиоты при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121 (10–2):86–91. (Verugina NI, Levin OS, Lyashenko EA. The role of the gut microbiota in Parkinson’s disease. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(10–2):86–91 (In Russ.)).

EDN: YNSOFS. https://doi.org/10.17116/jnevro202112110286

2. Гапонов Д.О., Пригодина Е.В., Грудина Т.В., Доросевич А.Е. Современный взгляд на патогенетические механизмы прогрессирования болезни Паркинсона. РМЖ. 2018;26(12–1):66–72. (Gaponov DO, Prigodina EV, Grudina TV, Dorosevich AE. Modern view on the pathogenetic mechanisms of Parkinson’s disease progression. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2018;26(12–1):66–72 (In Russ.)). EDN: YOCITJ.

3. Султанова С.Г., Федорова Н.В., Веругина Н.И., Смоленцева И.Г. Влияние двусторонней глубокой стимуляции субталамического ядра на ходьбу и равновесие у пациентов с болезнью Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2025:125(3):94–101. (Sultanova SG, Fedorova NV, Verugina NI, Smolentseva IG. The effect of bilateral subthalamic nucleus deep brain stimulation on gait and balance in patients with Parkinson’s disease. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(3):94–101 (In Russ.)).

EDN: FTKFRH. https://doi.org/10.17116/jnevro202512503194

4. Тютина Р.Р., Пилипович А.А., Голубев В.Л., Данилов Ал.Б. Микробиота и болезнь Паркинсона (обзор). Медицинский алфавит. 2020;(1):10–14. (Tyutina RR, Pilipovich AA, Golubev VL, Danilov AlB. Microbiota and Parkinson’s disease (overview). Meditsinskiy alfavit = Medical Alphabet. 2020;(1):10–14 (In Russ.)).

EDN: CQKDPE. https://doi.org/10.33667/2078-5631-2020-1-10-14

5. Левин О.С., Артемьев Д.В., Бриль Е.В., Кулуа Т.К. Болезнь Паркинсона: современные подходы к диагностике и лечению. Практическая медицина. 2017;1(1):45–51. (Levin OS, Artemyev DV, Bril EV, Kulua TK. Parkinson's disease: Modern approaches to diagnosis and treatment. Prakticheskaya meditsina = Practical medicine. 2017;1(1):45–51 (In Russ.)). EDN: YHZKNP.

6. Бриль Е.В., Томский А.А., Гамалея А.А., Поддубская А.А., Кесарев Д.Г., Федорова Н.В. Синдром отмены нейростимуляции у пациентов с болезнью Паркинсона – редкое неотложное состояние в неврологии и нейрохирургии. Анналы клинической и экспериментальной неврологии. 2024;18(3):91–102. (Bril EV, Tomskiy AA, Gamaleya AA, Poddubskaya AA, Kesarev DG, Fedorova NV. Deep brain stimulation withdrawal syndrome, a rare life-threatening condition in neurology and neurosurgery. Annaly klinicheskoy i eksperimental’noy nevrologii = Annals of Clinical and Experimental Neurology. 2024;18(3):91–102 (In Russ.)). EDN: IAQKXW.

https://doi.org/10.17816/ACEN.1095

7. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol. 2009;8(1):67–81.

PMID: 19081516. https://doi.org/10.1016/S1474-4422(08)70291-6

8. Lozano AM, Lipsman N, Bergman H, Brown P, Chabardes S, Chang JW et al. Deep brain stimulation: Current challenges and future directions. Nat Rev Neurol. 2019;15(3):148–60.

PMID: 30683913. PMCID: PMC6397644. https://doi.org/10.1038/s41582-018-0128-2

9. Krauss JK, Lipsman N, Aziz T, Boutet A, Brown P, Chang JW et al. Technology of deep brain stimulation: Current status and future trends. Nat Rev Neurol. 2021;17(2):75–87.

PMID: 33244188. PMCID: PMC7116699. https://doi.org/10.1038/s41582-020-00426-z

10. Little S, Brown P. The functional role of beta oscillations in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20 Suppl 1:S44–48.

PMID: 24262186. https://doi.org/10.1016/S1353-8020(13)70013-0

11. Bronte-Stewart HM, Beudel M, Ostrem JL, Little S, Almeida L, Ramirez-Zamora A et al.; ADAPT-PD Investigators. Long-term personalized adaptive deep brain stimulation in Parkinson disease: a nonrandomized clinical trial. JAMA Neurol. 2025;82(11):1171–80.

PMID: 40982287. PMCID: PMC12455485. https://doi.org/10.1001/jamaneurol.2025.2781

12. Guidetti M, Marceglia S, Bocci T, Duncan R, Fasano A, Foote KD et al. Physical therapy in patients with Parkinson’s disease treated with deep brain stimulation: A Delphi panel study. medRxiv (Preprint). 2024:2024.09.20.24314037.

PMID: 39399050. PMCID: PMC11469472. https://doi.org/10.1101/2024.09.20.24314037. Update in: J Neuroeng Rehabil. 2025;22(1):80. https://doi.org/10.1186/s12984-025-01616-w

13. Oulu University Repository. Kahkola J. Personalized deep brain stimulation for Parkinson’s disease. 2024.

URL: https://www.oulu.fi/en/theses/personalized-deep-brain-stimulation-for-parkinsons-disease (date of access – 10.06.2026).

14. Troster AI. Developments in the prediction of cognitive changes following deep brain stimulation in persons with Parkinson’s disease. Expert Rev Neurother. 2024;24(7):643–59.

PMID: 38814926. https://doi.org/10.1080/14737175.2024.236012

15. Neumann WJ, Gilron R, Little S, Tinkhauser G. Adaptive deep brain stimulation: From experimental evidence toward practical implementation. Mov Disord. 2023;38(6):937–48.

PMID: 37148553. https://doi.org/10.1002/mds.29415

16. Lozano AM, Lipsman N, Bergman H, Brown P, Chabardes S, Chang JW et al. Deep brain stimulation: Current challenges and future directions. Nat Rev Neurol. 2019;15(3):148–60.

PMID: 30683913. PMCID: PMC6397644. https://doi.org/10.1038/s41582-018-0128-2

17. Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K et al.; German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med. 2006;355(9):896–908.

PMID: 16943402. https://doi.org/10.1056/NEJMoa060281. Erratum in: N Engl J Med. 2006;355(12):1289.

18. Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nat Rev Neurol. 2019;15(4):234–42.

PMID: 30778210. https://doi.org/10.1038/s41582-019-0145-9

19. Бриль Е.В., Томский А.А., Гамалея А.А. Место DBS в лечении болезни Паркинсона. Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений. 2022;(2):23–25. (Bril EV, Tomsky AA, Gamaleya AA. The role of DBS in the treatment of Parkinson’s disease. Byulleten’ Natsional’nogo obshchestva po izucheniyu bolezni Parkinsona i rasstroystv dvizheniy = Bulletin of the National Society for the Study of Parkinson’s Disease and Movement Disorders. 2022;(2):23–25 (In Russ.)).

EDN: PHSNCY. https://doi.org/10.24412/2226-079X-2022-12428

20. Sandoval-Pistorius SS, Hacker ML, Waters AC, Wang J, Provenza NR, de Hemptinne C et al. Advances in deep brain stimulation: From mechanisms to applications. J Neurosci. 2023;43(45):7575-7586.

PMID: 37940596. PMCID: PMC10634582. https://doi.org/10.1523/JNEUROSCI.1427-23.2023.

21. Fenoy AJ, Simpson RK Jr. Risks of common complications in deep brain stimulation surgery: Management and avoidance. J Neurosurg. 2014;120(1):132–39.

PMID: 24236657. https://doi.org/10.3171/2013.10.JNS131225

22. Conway ZJ, Silburn PA, Perera T, O’Maley K, Cole MH. Low-frequency STN-DBS provides acute gait improvements in Parkinson’s disease: A double-blinded randomised cross-over feasibility trial. J Neuroeng Rehabil. 2021;18(1):125.

PMID: 34376190. PMCID: PMC8353795. https://doi.org/10.1186/s12984-021-00921-4

23. Hong J, Xie H, Chen Y, Liu D, Wang T, Xiong K, Mao Z. Effects of STN-DBS on cognition and mood in young-onset Parkinson’s disease: A two-year follow-up. Front Aging Neurosci. 2024;15:1177889.

PMID: 38292047. PMCID: PMC10824910. https://doi.org/10.3389/fnagi.2023.1177889

24. Cryan JF, O’Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877–2013.

PMID: 31460832. https://doi.org/10.1152/physrev.00018.2018

25. Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018;1693(Pt B):128–33.

PMID: 29903615. PMCID: PMC6005194. https://doi.org/10.1016/j.brainres.2018.03.015

26. Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease – from basic research to the clinic. Nat Rev Neurol. 2022;18(8):476–95. PMID: 35750883. https://doi.org/10.1038/s41582-022-00681-2

27. Li X, Hao X, Chen C, Zhai C, Pan T, Zhou X et al. Trends and hotspots on the relationship between gut microbiota and Parkinson’s disease: A bibliometric analysis. Front Cell Infect Microbiol. 2024;14:1421270.

PMID: 39403202. PMCID: PMC11472709. https://doi.org/10.3389/fcimb.2024.1421270

28. Jin X, Wei J, Min X, Fan Y, Yuan Z, Du Z et al. Gut microbiota and Parkinson’s disease: Exploring pathogenesis and potential therapeutic strategies. iScience. 2025;28(2):109012.

PMID: 41585498. PMCID: PMC12830195. https://doi.org/10.1016/j.isci.2025.114185

29. Beas R, Riva‑Moscoso A, Montalvan‑Sanchez E, Príncipe‑Meneses FS, Aljaras R, Ramirez‑Rojas M et al. Prevalence of small intestinal bacterial overgrowth in patients with gastroparesis: A systematic review and meta‑analysis. Gastroenterol Hepatol Bed Bench. 2023;16(1):438–47.

PMID: 37070116. PMCID: PMC10105503. https://doi.org/10.22037/ghfbb.v16i1.2652

30. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna). 2003;110(5):517–36.

PMID: 12721813. https://doi.org/10.1007/s00702-002-0808-2

31. Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S et al. Transneuronal Propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron. 2019;103(4):627–41.e7.

PMID: 31255487. PMCID: PMC6706297. https://doi.org/10.1016/j.neuron.2019.05.035

32. Svensson E, Horvath-Puho E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, Sørensen HT. Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol. 2015;78(4):522–529.

PMID: 26031848. https://doi.org/10.1002/ana.24448

33. Jia X, Wang Q, Liu M, Ding J. The interplay between gut microbiota and the brain-gut axis in Parkinson’s disease treatment. Front Neurol. 2024;15:1415463.

PMID: 38867886. PMCID: PMC11168434. https://doi.org/10.3389/fneur.2024.1415463

34. Houser MC, Tansey MG. The gut-brain axis: Is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? NPJ Parkinsons Dis. 2017;3:3.

PMID: 28649603. PMCID: PMC5445611. https://doi.org/10.1038/s41531-016-0002-0

35. Perez-Pardo P, Dodiya HB, Engen PA, Forsyth CB, Huschens AM, Shaikh M et al. Role of TLR4 in the gut-brain axis in Parkinson’s disease: A translational study from mice to human. Gut. 2019;68(5):829–43.

PMID: 30554160. https://doi.org/10.1136/gutjnl-2018-316844

36. ORBilu. University of Luxemburg. Open Repository and Bibliography. Novikova P. Systematic characterization of human gut microbiome in relation to Parkinson’s disease. URL: https://orbilu.uni.lu/handle/10993/62565 (date of access – 10.06.2026).

37. Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Burmann J et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66–72.

PMID: 27591074. https://doi.org/10.1016/j.parkreldis.2016.08.019

38. Wang L, Cui Y, Han B, Du Y, Salewala KS, Wang S et al. Gut microbiota and Parkinson’s disease. Chin Med J (Engl). 2025;138(3):289–97.

PMID: 39501822. PMCID: PMC11771718. https://doi.org/10.1097/CM9.0000000000003318

39. Chao YX, Gulam MY, Chia NSJ, Feng L, Rotzschke O, Tan EK. Gut-brain axis: Potential factors involved in the pathogenesis of Parkinson’s disease. Front Neurol. 2020;11:849.

PMID: 32982910. PMCID: PMC7477379. https://doi.org/10.3389/fneur.2020.00849. Erratum in: Front Neurol. 2020;11:625446.

https://doi.org/10.3389/fneur.2020.625446.